IntraBio Acquisition, Valuation, Funding & Investors

United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. The majority of the company's sales are generated in China, followed by Europe, India and other countries.

Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.

Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others.

Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Shilpa Medicare makes active pharmaceutical ingredients, formulations and biologics, with oncology a core area. It also has contract development and manufacturing work and sells to pharma companies in India and overseas. Headquartered in Bengaluru, with plants in Karnataka and Telangana.

Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company’s reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.

ArsenalBio is a South San Francisco-based, clinical-stage cell therapy company that engineers CAR T-cell therapies using CRISPR-based genome editing and logic-gating technology. Its pipeline targets solid tumors including ovarian, kidney, and prostate cancers, with its lead candidate, AB-2100, in Phase 1/2 trials for clear-cell renal cell carcinoma under a collaboration with Bristol-Myers Squibb. The platform is designed to address T-cell exhaustion, tumor specificity, and genome toxicity, challenges that have limited CAR T therapies in solid tumors.

BioRay Pharmaceuticals is a Shanghai-headquartered biopharma with R&D centers in Taizhou, Hangzhou, San Diego, and over 1,400 employees focused on immunology therapies. It commercializes three products in China for autoimmune diseases including Telitacicept for SLE, with a pipeline of 20 preclinical and 10 clinical assets targeting cancer and inflammation. Founded in 2010, BioRay operates GMP facilities for full-cycle development.

Inari is a West Lafayette-headquartered biotechnology company developing seed traits through multiplex gene editing and predictive design via its SEEDesign platform. The firm targets corn, soybean, and wheat improvements for yield, drought tolerance, and nitrogen use efficiency. Founded in 2016, Inari operates greenhouses and field trial sites across the US Midwest and Brazil. It collaborates with Corteva and Bayer on commercialization pipelines for hybrid varieties suited to diverse climates.

Orano Med is a Maisons-Alfort-headquartered developer of targeted alpha therapies for prostate and other cancers using bismuth-213 and lead-212 isotopes. Part of the Orano nuclear group, the company produces chelating agents and ensures isotope supply chains from facilities in France and Belgium for clinical-stage treatments.